{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:30Z","timestamp":1790035050733,"version":"4.0.1"},"reference-count":50,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Advanced-stage mycosis fungoides (MF) and S\u00e9zary syndrome (SS) are aggressive forms of cutaneous T-cell lymphoma (CTCL) for which treatment options are limited and prognosis is poor. Brentuximab vedotin (BV), an anti-CD30 antibody\u2013drug conjugate, has demonstrated high response rates in patients with CD30 expression \u2265 10%. However, data on its efficacy in cases with low CD30 expression (&lt;10%) remain scarce. Methods: This retrospective analysis evaluated the real-world efficacy of BV in patients with advanced-stage MF\/SS and low CD30 expression. A retrospective analysis was conducted on 32 patients across 11 German CTCL expert centers. All patients had advanced-stage MF or SS with CD30 expression &lt; 10% and received BV at the standard dose. Treatment response was assessed using EORTC-ISCL criteria. Results: All patients had received prior systemic therapies (median: 3) with 36% having undergone prior mono- or polychemotherapy. The study population included 30 MF (stage IIB) and two SS cases. The overall response rate (ORR) in this population was 53.1% (17\/32). A complete response (CR) was achieved in 12.5% (4\/32), a partial response (PR) was achieved in 40.6% (13\/32), stable disease (SD) was seen in 18.8% (6\/32), and progressive disease (PD) was seen in 28.1% (9\/32). The median progression-free survival (PFS) was 4.0 months (arithmetic mean: 6.38; range: 0.5\u201315.5), and the median time to next treatment (TTNT) was 7.25 months (arithmetic mean: 7.30; range: 2.00\u201315.5). Conclusions: BV demonstrated encouraging activity in heavily pretreated advanced MF\/SS with low CD30 expression, achieving an ORR comparable to that observed in patients with higher CD30 levels. While response rates were similar, PFS was shorter. These findings suggest that BV remains a potential therapeutic option in this patient population and merits further prospective investigation.<\/jats:p>","DOI":"10.3390\/cancers18010097","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:47:27Z","timestamp":1766998047000},"page":"97","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides\/S\u00e9zary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network"],"prefix":"10.3390","volume":"18","author":[{"given":"Christoph","family":"Blazejak","sequence":"first","affiliation":[{"name":"Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University D\u00fcsseldorf-Krefeld, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Oymanns","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University D\u00fcsseldorf-Krefeld, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Stranzenbach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e4tsklinikum Bochum, 44801 Bochum, Germany"},{"name":"Dermatology Practice Dr. R. Stranzenbach, 58285 Gevelsberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Hillen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Vivantes Klinikum Neuk\u00f6lln, 12351 Berlin, Germany"},{"name":"MVZ Dermatopathologie Duisburg Essen GmbH, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Mitteldorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center G\u00f6ttingen, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Mannheim, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6293-2554","authenticated-orcid":false,"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schr\u00fcfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Hospital W\u00fcrzburg, 97080 W\u00fcrzburg, Germany"},{"name":"Skinmed AG, 5600 Lenzburg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"Gosmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, 32429 Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, 24105 Kiel, Germany"},{"name":"Medical School Hamburg, University of Applied Sciences and Medical University, 20457 Hamburg, Germany"},{"name":"Helios Kliniken GmbH, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7692-9240","authenticated-orcid":false,"given":"Nina","family":"Booken","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-499X","authenticated-orcid":false,"given":"Alexander","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Helios Klinikum Oberhausen, Universit\u00e4t Witten\/Herdecke, 46045 Oberhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Dippel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Klinikum Ludwigshafen, 67063 Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Tumor Center, Municipal Hospital Karlsruhe, Academic Teaching Hospital of the University of Freiburg, 76133 Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Weyermann","sequence":"additional","affiliation":[{"name":"Department of Health Care, Niederrhein University of Applied Sciences, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, 32429 Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University D\u00fcsseldorf-Krefeld, 47805 Krefeld, Germany"},{"name":"Institute for Molecular Medicine, Medical School Hamburg, University of Applied Sciences and Medical University, 20457 Hamburg, Germany"},{"name":"Faculty of Medicine, Health and Medical University D\u00fcsseldorf-Krefeld, 47805 Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival Outcomes and Prognostic Factors in Mycosis Fungoides\/S\u00e9zary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer Staging Proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S\u00e9zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dobos, G., Pohrt, A., Ram-Wolff, C., Lebb\u00e9, C., Bouaziz, J.-D., Battistella, M., Bagot, M., and de Masson, A. (2020). Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers, 12.","DOI":"10.3390\/cancers12102921"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cheikh El Najjarine, K., Kaj\u00fcter, H., Wellmann, I., Stang, A., and Assaf, C. (2025). Incidence and Mortality of Cutaneous Lymphomas in Germany. J. Dtsch. Dermatol. Ges., online ahead of print.","DOI":"10.1111\/ddg.15904"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2013Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_9","unstructured":"NCCN (2025, November 26). Primary Cutaneous Lymphomas, Version 2025. Available online: https:\/\/www.nccn.org."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Alberti-Violetti, S., Ardig\u00f2, M., Massone, C., Pileri, A., Sala, R., Teoli, M., Grandi, V., Quaglino, P., Pimpinelli, N., and Berti, E. (2024). Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: A multicenter real-life evaluation. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1298296"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: A comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Assaf, C., Illidge, T.M., Waser, N., He, M., Li, T., Zomas, A., Bent-Ennakhil, N., Little, M., Ortiz-Romero, P.L., and Pimpinelli, N. (2023). A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed\/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. Cancers, 15.","DOI":"10.3390\/cancers15235669"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bjd.18535","article-title":"Brentuximab a novel antibody therapy: Real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma","volume":"182","author":"Engelina","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity*","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jdv.18563","article-title":"Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","volume":"37","author":"Muniesa","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clml.2023.10.001","article-title":"Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States","volume":"24","author":"Barta","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Campbell, B.A., Scarisbrick, J.J., Kim, Y.H., Wilcox, R.A., McCormack, C., and Prince, H.M. (2020). Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12082311"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","article-title":"Production of a monoclonal antibody specific for Hodgkin and Sternberg\u2013Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells","volume":"299","author":"Schwab","year":"1982","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V74.5.1678.1678","article-title":"BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol- resistant epitope","volume":"74","author":"Schwarting","year":"1989","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","article-title":"The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas","volume":"14","author":"Karube","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/bjd.19823","article-title":"Most rare subtypes of cutaneous lymphoma display variable CD30 expression: Analysis of the German Cutaneous Lymphoma Network","volume":"185","author":"Wehkamp","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.70107","article-title":"CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas","volume":"101","author":"Stein","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"mAbs"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Dong, S., and Wang, Y. (2025). Antibody\u2013Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism. Cancers, 17.","DOI":"10.3390\/cancers17030496"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cyto.b.21940","article-title":"Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma","volume":"100","author":"Debliquis","year":"2020","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/his.14660","article-title":"Intraindividual variability of CD30 expression in mycosis fungoides \u2013implications for diagnostic evaluation and therapy","volume":"81","author":"Mitteldorf","year":"2022","journal-title":"Histopathology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ejca.2018.07.305","article-title":"Updated combined analysis of two phase II studies of brentuximab vedotin in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"101","author":"Huen","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"156098","DOI":"10.1016\/j.prp.2025.156098","article-title":"Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation","volume":"272","author":"Shi","year":"2025","journal-title":"Pathol. Res. Pr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/exd.12873","article-title":"The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides","volume":"25","author":"Furudate","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/exd.12894","article-title":"Mac attack: Macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis","volume":"25","author":"Assaf","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11887","DOI":"10.18632\/oncotarget.24472","article-title":"Brentuximab vedotin: Targeting CD30 as standard in CTCL","volume":"9","author":"Prince","year":"2018","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, Z., Guo, W., and Bai, O. (2023). Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1301437"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cup.14178","article-title":"Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction","volume":"49","author":"Hofer","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/DAD.0000000000002330","article-title":"QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma","volume":"45","author":"Cieslak","year":"2023","journal-title":"Am. J. Dermatopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/bjd\/ljac012","article-title":"Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma","volume":"188","author":"Oymanns","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Schummer, P., Glatzel, C., Schr\u00fcfer, P., Lawrenz, I., Dobos, G., Wehkamp, U., H\u00fcning, S., Stranzenbach, R., Nicolay, J.P., and Goebeler, M. (2025). Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma\u2014A retrospective multicenter analysis. JDDG J. Dtsch. Dermatol. Ges.","DOI":"10.1111\/ddg.15897"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1159\/000511111","article-title":"Successful Treatment of a Patient with Brentuximab Vedotin-Refractory ALK-Negative Anaplastic Large Cell Lymphoma with Romidepsin","volume":"13","author":"Jo","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/CCO.0000000000000272","article-title":"Experimental treatment strategies in primary cutaneous T-cell lymphomas","volume":"28","author":"Rozati","year":"2016","journal-title":"Curr. Opin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/97\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:57:34Z","timestamp":1766998654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/97"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010097"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010097","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}